Accessibility Menu

Bio-Techne(FRA) TE1

Market Cap€9.68BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPON/A
5 YearN/A
1 YearN/A
1 MonthN/A
€61.78
-0.32%
-0.20Today

Bio-Techne Financials at a Glance

Market Cap

€9.68BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

€1.04K

Net Income (TTM)

€155.94

EPS (TTM)

€0.99

P/E Ratio

62.14

Dividend

€0.27

Beta (Volatility)

-0.01 (Low)

Price

€61.78

Volume

0

Open

€61.68

Previous Close

€61.78

Daily Range

€61.68 - €61.78

52-Week Range

€37.03 - €63.02

Estimated Earnings Date

N/A

TE1 News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Bio-Techne

Bio-Techne Corp. engages in the development, manufacture and sale of biotechnology reagents and instruments for the research and clinical diagnostic markets. It operates through the following segments: Protein Sciences and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures purified proteins and reagent solutions most notably cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents and T-Cell activation technologies. This segment also includes protein analysis solutions that offer researchers efficient and streamlined options for automated western blot and multiplexed ELISA workflow. The Diagnostics & Genomics segment develops and manufactures diagnostic products, including FDA-regulated controls, calibrators, blood gas and clinical chemistry controls and other reagents for OEM and clinical customers, as well as a portfolio of clinical molecular diagnostic oncology assays, including the ExoDx Prostate (IntelliScore) test (EPI) for prostate cancer diagnosis. This segment also manufactures and sells advanced tissue-based in-situ hybridization assays (ISH) for research and clinical use. The company was founded in 1976 and is headquartered in Minneapolis, MN.

Industry

Life Sciences Tools and Services

Employees

3,000

CEO

Kim Kelderman

TE1 Financials

Key Financial Metrics (TTM)

Gross Margin

N/A

Operating Margin

N/A

Net Income Margin

N/A

Return on Equity

8.97%

Return on Capital

N/A

Return on Assets

N/A

Earnings Yield

1.61%

Dividend Yield

0.44%

Payout Ratio

N/A

Stock Overview

Market Cap

€9.68BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

156.82M

Volume

0

Avg. Volume

0.152

Financials (TTM)

Gross Profit

N/A

Operating Income

N/A

EBITDA

N/A

Operating Cash Flow

N/A

Capital Expenditure

N/A

Free Cash Flow

N/A

Cash & ST Invst.

N/A

Total Debt

N/A

Bio-Techne Performance Analysis

Bio-Techne annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-06-30EUR 1,087,160,13710.7%
20242024-06-30EUR 1,071,863,544-1.4%
20252025-06-30EUR 1,121,762,7734.7%
20262026-06-30EUR 1,041,700,292-7.1%
Bio-Techne annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-06-30EUR 1.6914.5%
20242024-06-30EUR 0.97-42.6%
20252025-06-30EUR 0.42-56.3%
20262026-06-30EUR 0.99135.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

€276.24

+1.0%

Gross Profit

€180.17

+1.0%

Gross Margin

65.22%

+1.0%

Market Cap

€9.68BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

€3.23

N/A

Employees

3,000

N/A

Net Income

€46.99

-3.0%

EBITDA

€88.48

+1.0%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

€484.39

-6.2%

Total Debt

€252.85

+0.7%

Accounts Receivable

€189.44

+1.1%

Inventory

€171.21

+1.1%

Long Term Debt

€239.79

+0.7%

Short Term Debt

€13.06

+1.1%

Return on Assets

6.90%

+2.4%

Return on Invested Capital

8.43%

+0.8%

Free Cash Flow

€75.71

+1.1%

Operating Cash Flow

€83.11

+1.1%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,684.24-0.00%
^DJIDJI
$53,254.61-0.01%
^IXICNASDAQ
$26,319.55-0.00%
BTCBitcoin
$78,890.00-0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
PCGPG&E
$13.27-0.20%
NVDANvidia
$220.78+0.01%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.97+0.11%
CNHCNH Industrial
$11.83+0.01%

Questions About TE1

What is the current price of Bio-Techne?

Bio-Techne is trading at €61.78 per share.

What is the 52-week range for Bio-Techne?

Over the past 52 weeks, Bio-Techne has traded between €37.03 and €63.02.

How much debt does Bio-Techne have?

As of the most recent reporting period, Bio-Techne reported total debt of €252.85M.

How much cash does Bio-Techne have on hand?

Bio-Techne reported €231.53M in cash and cash equivalents in its most recent financial results.

What is Bio-Techne’s dividend yield?

Bio-Techne currently has a dividend yield of 0.44%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.